RS50568B9 - Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze - Google Patents
Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinazeInfo
- Publication number
- RS50568B9 RS50568B9 RS20080109A RSP20080109A RS50568B9 RS 50568 B9 RS50568 B9 RS 50568B9 RS 20080109 A RS20080109 A RS 20080109A RS P20080109 A RSP20080109 A RS P20080109A RS 50568 B9 RS50568 B9 RS 50568B9
- Authority
- RS
- Serbia
- Prior art keywords
- inhibition
- compounds
- methods
- aurora kinase
- mitotic progression
- Prior art date
Links
- 102000003989 Aurora kinases Human genes 0.000 title 1
- 108090000433 Aurora kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000008600 mitotic progression Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Small-Scale Networks (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57165304P | 2004-05-14 | 2004-05-14 | |
| US61722104P | 2004-10-08 | 2004-10-08 | |
| EP05779921A EP1771450B9 (en) | 2004-05-14 | 2005-05-12 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
| PCT/US2005/016445 WO2005111039A2 (en) | 2004-05-14 | 2005-05-12 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RS50568B RS50568B (sr) | 2010-05-07 |
| RS50568B9 true RS50568B9 (sr) | 2019-06-28 |
| RS50568B8 RS50568B8 (sr) | 2019-08-30 |
Family
ID=35262144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20080109A RS50568B8 (sr) | 2004-05-14 | 2005-05-12 | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
| RS20120416A RS52436B (sr) | 2004-05-14 | 2005-05-12 | Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20120416A RS52436B (sr) | 2004-05-14 | 2005-05-12 | Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US7572784B2 (sr) |
| EP (4) | EP2719698B1 (sr) |
| JP (4) | JP4467616B2 (sr) |
| KR (3) | KR20120091275A (sr) |
| CN (1) | CN104193750B (sr) |
| AR (1) | AR049277A1 (sr) |
| AT (1) | ATE381566T1 (sr) |
| AU (1) | AU2005243175B2 (sr) |
| BR (1) | BRPI0511139B8 (sr) |
| CA (1) | CA2565411C (sr) |
| CY (2) | CY1108092T1 (sr) |
| DE (1) | DE602005003951T4 (sr) |
| DK (1) | DK1771450T5 (sr) |
| EA (1) | EA012112B1 (sr) |
| ES (3) | ES2540987T3 (sr) |
| HK (4) | HK1102500A1 (sr) |
| HR (2) | HRP20080120T5 (sr) |
| IL (1) | IL179063A (sr) |
| MX (1) | MXPA06013042A (sr) |
| MY (1) | MY139355A (sr) |
| NZ (1) | NZ551370A (sr) |
| PL (1) | PL1771450T3 (sr) |
| PT (2) | PT1771450E (sr) |
| RS (2) | RS50568B8 (sr) |
| TW (1) | TWI338688B (sr) |
| WO (1) | WO2005111039A2 (sr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1771450T3 (pl) | 2004-05-14 | 2008-05-30 | Millennium Pharm Inc | Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora |
| CN101068815B (zh) * | 2004-10-04 | 2012-09-05 | 千禧药品公司 | 有效作为蛋白激酶抑制剂的内酰胺化合物 |
| PE20060600A1 (es) * | 2004-10-29 | 2006-07-14 | Banyu Pharma Co Ltd | Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa |
| CN101166732B (zh) | 2005-04-28 | 2013-04-17 | 田边三菱制药株式会社 | 氰基吡啶衍生物及其作为药物的应用 |
| KR101332904B1 (ko) * | 2005-05-05 | 2013-11-26 | 크로마 세러퓨틱스 리미티드 | 효소 및 수용체 조작 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| WO2007087246A2 (en) * | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
| JP2009530274A (ja) * | 2006-03-15 | 2009-08-27 | ワイス | ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物 |
| WO2007107469A1 (en) * | 2006-03-20 | 2007-09-27 | F. Hoffmann-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| CA2649913A1 (en) * | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| EA200970361A1 (ru) | 2006-10-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы киназы |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| AU2014280932B2 (en) * | 2006-11-16 | 2016-10-06 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| AU2012203952B2 (en) * | 2006-11-16 | 2014-12-11 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
| WO2008147945A1 (en) * | 2007-05-24 | 2008-12-04 | Wyeth | Azacyclylbenzamide derivatives as histamine-3 antagonists |
| TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
| CL2008002088A1 (es) * | 2007-07-16 | 2008-09-05 | Wyeth Corp | Compuestos derivados de fenilo sustituido, moduladores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos tales como demencia, alzheimer, entre otros. |
| CN101835741A (zh) * | 2007-09-04 | 2010-09-15 | 比奥里波克斯公司 | 用于炎症治疗的双芳香族化合物 |
| EA201000316A1 (ru) * | 2007-09-12 | 2010-10-29 | ВАЙЕТ ЭлЭлСи | Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| JP2009108036A (ja) * | 2007-09-28 | 2009-05-21 | Fujifilm Corp | 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物 |
| GB0803747D0 (en) * | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| JP5555186B2 (ja) * | 2008-02-29 | 2014-07-23 | クロマ セラピューティクス リミテッド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| CA2722220C (en) | 2008-04-30 | 2016-06-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
| US20110112193A1 (en) * | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
| US7998952B2 (en) * | 2008-12-05 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | Thiolactams and uses thereof |
| JP5738196B2 (ja) * | 2008-12-22 | 2015-06-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用 |
| TW201100381A (en) | 2009-03-12 | 2011-01-01 | Biolipox Ab | Bis aromatic compounds for use as LTC4 synthase inhibitors |
| JP2012520275A (ja) | 2009-03-12 | 2012-09-06 | バイオリポックス エービー | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 |
| US20110319431A1 (en) | 2009-03-12 | 2011-12-29 | Biolipox Ab | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| US20120035217A1 (en) | 2009-03-12 | 2012-02-09 | Biolipox Ab | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| US8518933B2 (en) | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| US8546377B2 (en) * | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| JP2013520424A (ja) * | 2010-02-19 | 2013-06-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| EP2545036A1 (en) | 2010-03-12 | 2013-01-16 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN103804391A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CN103408552B (zh) * | 2013-07-25 | 2015-07-01 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| JP2018524292A (ja) * | 2015-07-21 | 2018-08-30 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼインヒビターと化学療法剤の投与 |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| CA3124330A1 (en) | 2018-12-21 | 2020-06-25 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| CN112062768B (zh) * | 2020-07-20 | 2021-08-31 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 具有Aurora激酶降解活性的小分子及其制备方法和应用 |
| JP2025503429A (ja) * | 2021-12-14 | 2025-02-04 | プレーザー セラピューティクス インコーポレイティド | ポリユビキチン化による標的タンパク質またはポリペプチドの分解用の新規化合物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022801A (en) | 1974-06-03 | 1977-05-10 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
| US3947585A (en) | 1974-06-03 | 1976-03-30 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
| US4028381A (en) | 1975-05-05 | 1977-06-07 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
| US4099012A (en) * | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4547581A (en) | 1979-02-07 | 1985-10-15 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines and intermediates in their preparation |
| FR2450833A1 (fr) | 1979-02-07 | 1980-10-03 | Hoffmann La Roche | Derives de benzazepine |
| US4481142A (en) * | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| KR840000061B1 (ko) | 1979-02-07 | 1984-01-31 | 에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트 | 벤즈아제핀 유도체의 제조방법 |
| US4318854A (en) | 1979-02-07 | 1982-03-09 | Hoffmann-La Roche Inc. | Intermediates in the production of 2-benzazepines |
| ZA80492B (en) * | 1979-02-07 | 1981-01-28 | Hoffmann La Roche | Benzazepine derivatives |
| US4469633A (en) * | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| NL8102182A (nl) | 1981-05-04 | 1982-12-01 | Philips Nv | Kleurenbeeldbuis. |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) * | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) * | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| CA2247453A1 (en) | 1996-03-08 | 1997-09-12 | Joseph James Lewis | Azolobenzazepine derivatives as neurologically active agents |
| WO1998028281A1 (en) | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| AU744636B2 (en) | 1997-09-29 | 2002-02-28 | Meiji Seika Pharma Co., Ltd. | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic |
| US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US7115739B2 (en) * | 2000-09-15 | 2006-10-03 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
| AU2002255452B2 (en) * | 2000-12-21 | 2006-06-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| CA2454417A1 (en) | 2001-08-09 | 2003-02-20 | Actelion Pharmaceuticals Ltd. | Novel benzo-fused heterocycles as endothelin antagonists |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| PL1771450T3 (pl) * | 2004-05-14 | 2008-05-30 | Millennium Pharm Inc | Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora |
| WO2006055831A2 (en) | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
-
2005
- 2005-05-12 PL PL05779921T patent/PL1771450T3/pl unknown
- 2005-05-12 CA CA2565411A patent/CA2565411C/en active Active
- 2005-05-12 JP JP2007513304A patent/JP4467616B2/ja active Active
- 2005-05-12 EP EP13189935.3A patent/EP2719698B1/en active Active
- 2005-05-12 AU AU2005243175A patent/AU2005243175B2/en active Active
- 2005-05-12 BR BRPI0511139A patent/BRPI0511139B8/pt active IP Right Grant
- 2005-05-12 KR KR1020127014200A patent/KR20120091275A/ko active Search and Examination
- 2005-05-12 CN CN201410345955.0A patent/CN104193750B/zh active Active
- 2005-05-12 EP EP10178391.8A patent/EP2261226B1/en active Active
- 2005-05-12 EP EP13189940.3A patent/EP2746285B1/en active Active
- 2005-05-12 ES ES10178391.8T patent/ES2540987T3/es active Active
- 2005-05-12 EP EP05779921A patent/EP1771450B9/en active Active
- 2005-05-12 US US11/127,855 patent/US7572784B2/en active Active
- 2005-05-12 RS RS20080109A patent/RS50568B8/sr unknown
- 2005-05-12 KR KR1020067026332A patent/KR101792651B1/ko active IP Right Grant
- 2005-05-12 PT PT05779921T patent/PT1771450E/pt unknown
- 2005-05-12 EA EA200602100A patent/EA012112B1/ru not_active IP Right Cessation
- 2005-05-12 RS RS20120416A patent/RS52436B/sr unknown
- 2005-05-12 ES ES07024446T patent/ES2391577T3/es active Active
- 2005-05-12 ES ES05779921T patent/ES2299080T3/es active Active
- 2005-05-12 PT PT07024446T patent/PT1905773E/pt unknown
- 2005-05-12 WO PCT/US2005/016445 patent/WO2005111039A2/en active Application Filing
- 2005-05-12 MX MXPA06013042A patent/MXPA06013042A/es active IP Right Grant
- 2005-05-12 MY MYPI20052151A patent/MY139355A/en unknown
- 2005-05-12 AT AT05779921T patent/ATE381566T1/de active
- 2005-05-12 KR KR1020137013571A patent/KR101748290B1/ko active IP Right Grant
- 2005-05-12 NZ NZ551370A patent/NZ551370A/en unknown
- 2005-05-12 DE DE602005003951T patent/DE602005003951T4/de active Active
- 2005-05-12 DK DK05779921.5T patent/DK1771450T5/da active
- 2005-05-13 TW TW094115612A patent/TWI338688B/zh active
- 2005-05-16 AR ARP050102001A patent/AR049277A1/es unknown
-
2006
- 2006-11-06 IL IL179063A patent/IL179063A/en active IP Right Grant
- 2006-12-21 US US11/643,600 patent/US20070185087A1/en not_active Abandoned
-
2007
- 2007-10-03 HK HK07110701A patent/HK1102500A1/xx unknown
-
2008
- 2008-03-17 CY CY20081100297T patent/CY1108092T1/el unknown
- 2008-03-19 HR HRP20080120TT patent/HRP20080120T5/hr unknown
- 2008-05-08 JP JP2008122788A patent/JP5148358B2/ja active Active
- 2008-09-18 HK HK08110327.5A patent/HK1114853A1/xx unknown
-
2009
- 2009-05-27 US US12/472,583 patent/US8399659B2/en active Active
-
2011
- 2011-09-16 JP JP2011203714A patent/JP2012006972A/ja not_active Withdrawn
-
2012
- 2012-10-02 HR HRP20120785TT patent/HRP20120785T1/hr unknown
- 2012-10-03 US US13/644,216 patent/US9102678B2/en active Active
- 2012-10-16 CY CY20121100962T patent/CY1113192T1/el unknown
-
2014
- 2014-02-14 JP JP2014026015A patent/JP5827708B2/ja active Active
- 2014-12-23 HK HK14112844.7A patent/HK1199254A1/xx unknown
-
2015
- 2015-06-08 HK HK15105404.2A patent/HK1205102A1/xx unknown
- 2015-07-27 US US14/810,225 patent/US9765078B2/en active Active
-
2017
- 2017-09-18 US US15/707,484 patent/US10414770B2/en active Active
-
2019
- 2019-09-13 US US16/569,809 patent/US11014928B2/en active Active
-
2021
- 2021-05-24 US US17/328,618 patent/US20220041605A1/en not_active Abandoned
-
2023
- 2023-10-19 US US18/490,596 patent/US20240083906A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1205102A1 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
| ME00716B (me) | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze | |
| EP1957078A4 (en) | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER BY INHIBITING AURORA KINASE | |
| HK1096972A1 (en) | Inhibition of syk kinase expression | |
| IL189933A0 (en) | Rna antagonist compounds for the inhibition of apo-b100 expression | |
| EP2121637A4 (en) | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | |
| HK1217699A1 (zh) | 抑制有絲分裂的化合物 | |
| IL190727A0 (en) | Method of inhibiting flt3 kinase | |
| GB2432165B (en) | Method of inhibiting hydrate formation | |
| ZA200704106B (en) | Inhibitors of c-fms kinase | |
| EP1904457A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH | |
| HK1144392A1 (en) | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | |
| GB0608823D0 (en) | Inhibitors of P13 kinase | |
| ZA200700826B (en) | Thienopyrimidines useful as Aurora kinase inhibitors | |
| ZA200809874B (en) | Method of inhibiting c kit kinase | |
| IL172375A0 (en) | Chinazoline derivatives as aurora kinase inhibitors | |
| IL182735A0 (en) | Inhibitors of c-fms kinase | |
| EP1906967A4 (en) | ABL Kinase Inhibition | |
| IL182680A0 (en) | Compositions and methods for short interfering nucleic acid inhibition of | |
| EP1778693A4 (en) | AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL | |
| SI1905773T1 (sl) | Spojine in postopki za inhibiranje mitotične progresije z inhibiranjem aurora kinaze | |
| SI1771450T1 (sl) | Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora | |
| EP1771203A4 (en) | INHIBITION OF NF-KB | |
| EP1765334A4 (en) | PRODRUGS OF INHIBITORS OF MITOTIC KINESINE | |
| GB0410299D0 (en) | Inhibition of biofilm formation |